Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2025-03-05 Purchase |
2025-03-07 6:05 pm |
Janux Therapeutics Inc. | JANX | RA CAPITAL MANAGEMENT L.P. RA Capital Healthcare Fund LP RA Capital Nexus Fund II L.P. Kolchinsky Peter Shah Rajeev M. Director 10% Owner |
824,041 | $30.75 | $25,342,965 | 11,189,693 (Indirect) |
View |
| 2025-03-03 Sale |
2025-03-05 8:00 pm |
Janux Therapeutics Inc. | JANX | Meyer Andrew Hollman Chief Business Officer |
3,334 | $32.15 | $107,174 | 176,138 (Direct) |
View |
| 2025-02-03 Sale |
2025-02-05 8:00 pm |
Janux Therapeutics Inc. | JANX | Meyer Andrew Hollman Chief Business Officer |
3,334 | $42.29 | $140,999 | 179,472 (Direct) |
View |
| 2025-01-07 Sale |
2025-01-08 8:00 pm |
Janux Therapeutics Inc. | JANX | Campbell David Alan President and CEO |
5,000 | $60 | $300,004 | 293,054 (Direct) |
View |
| 2025-01-02 Sale |
2025-01-03 5:10 pm |
Janux Therapeutics Inc. | JANX | Meyer Andrew Hollman Chief Business Officer |
13,334 | $54.88 | $731,785 | 145,139 (Direct) |
View |
| 2024-12-24 Sale |
2024-12-27 8:00 pm |
Janux Therapeutics Inc. | JANX | Campbell David Alan President and CEO |
25,000 | $56.19 | $1,404,805 | 217,054 (Direct) |
View |
| 2024-12-03 Sale |
2024-12-03 8:00 pm |
Janux Therapeutics Inc. | JANX | Campbell David Alan President and CEO |
15,000 | $67 | $1,005,000 | 242,054 (Direct) |
View |
| 2024-11-25 Sale |
2024-11-27 8:00 pm |
Janux Therapeutics Inc. | JANX | Campbell David Alan President and CEO |
25,000 | $51.6 | $1,289,879 | 257,054 (Direct) |
View |
| 2024-10-28 Sale |
2024-10-30 7:30 pm |
Janux Therapeutics Inc. | JANX | Campbell David Alan President and CEO |
25,000 | $53.54 | $1,338,559 | 282,054 (Direct) |
View |
| 2024-09-13 Sale |
2024-10-24 4:15 pm |
Janux Therapeutics Inc. | JANX | Lichter Jay 10% Owner |
3,815 | $46.68 | $178,084 | 6,618,252 (Indirect Direct) |
View |
| 2024-10-18 Purchase |
2024-10-22 4:20 pm |
Janux Therapeutics Inc. | JANX | RA CAPITAL MANAGEMENT L.P. RA Capital Healthcare Fund LP RA Capital Nexus Fund II L.P. Kolchinsky Peter Shah Rajeev M. Director 10% Owner |
1,200,000 | $44.75 | $53,700,000 | 10,365,652 (Indirect) |
View |
| 2024-10-16 Sale |
2024-10-18 6:51 pm |
Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner |
1,673,128 | $46.3 | $77,472,371 | 4,281,533 (Indirect Direct) |
View |
| 2024-09-26 Sale |
2024-09-30 8:49 pm |
Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner |
307,779 | $46.96 | $14,452,394 | 3,005,777 (Indirect Direct) |
View |
| 2024-09-27 Sale |
2024-09-27 7:32 pm |
Janux Therapeutics Inc. | JANX | Meyer Andrew Hollman Chief Business Officer |
50,000 | $45.96 | $2,297,755 | 168,259 (Direct) |
View |
| 2024-09-27 Sale |
2024-09-27 7:31 pm |
Janux Therapeutics Inc. | JANX | DiRaimondo Thomas Chief Scientific Officer |
5,000 | $46.34 | $231,716 | 97,938 (Direct) |
View |
| 2024-09-27 Sale |
2024-09-27 7:30 pm |
Janux Therapeutics Inc. | JANX | Campbell David Alan President and CEO |
25,000 | $46.31 | $1,157,641 | 307,054 (Direct) |
View |
| 2024-09-10 Sale |
2024-09-12 8:42 pm |
Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner |
451,091 | $46.89 | $21,153,619 | 5,987,589 (Indirect Direct) |
View |
| 2024-09-06 Sale |
2024-09-10 5:02 pm |
Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner |
242,182 | $42 | $10,172,364 | 3,297,625 (Indirect Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-03-03 Exercise |
2025-03-05 8:00 pm |
N/A 2031-03-09 |
Janux Therapeutics Inc. | JANX | Meyer Andrew Hollman Chief Business Officer |
3,334 | $0 | 176,138 (Direct) |
View |
| 2025-03-03 Exercise |
2025-03-05 8:00 pm |
N/A N/A |
Janux Therapeutics Inc. | JANX | Meyer Andrew Hollman Chief Business Officer |
3,334 | $4.21 | 176,138 (Direct) |
View |
| 2025-02-03 Exercise |
2025-02-05 8:00 pm |
N/A 2031-03-09 |
Janux Therapeutics Inc. | JANX | Meyer Andrew Hollman Chief Business Officer |
3,334 | $0 | 179,472 (Direct) |
View |
| 2025-02-03 Exercise |
2025-02-05 8:00 pm |
N/A N/A |
Janux Therapeutics Inc. | JANX | Meyer Andrew Hollman Chief Business Officer |
3,334 | $4.21 | 179,472 (Direct) |
View |
| 2025-01-02 Option Award |
2025-01-03 8:10 pm |
N/A 2035-01-01 |
Janux Therapeutics Inc. | JANX | McIver Zachariah Chief Medical Officer |
117,000 | $0 | 117,000 (Direct) |
View |
| 2025-01-02 Option Award |
2025-01-03 8:10 pm |
N/A 2035-01-01 |
Janux Therapeutics Inc. | JANX | Winter Charles M. Chief Technical Officer |
103,500 | $0 | 157,788 (Direct) |
View |
| 2025-01-02 Option Award |
2025-01-03 8:10 pm |
N/A 2035-01-01 |
Janux Therapeutics Inc. | JANX | Campbell David Alan President and CEO |
364,500 | $0 | 581,554 (Direct) |
View |
| 2025-01-02 Option Award |
2025-01-03 8:10 pm |
N/A 2035-01-01 |
Janux Therapeutics Inc. | JANX | Robinson Byron Chief Strategy Officer |
126,000 | $0 | 126,000 (Direct) |
View |
| 2025-01-02 Option Award |
2025-01-03 8:10 pm |
N/A 2035-01-01 |
Janux Therapeutics Inc. | JANX | DiRaimondo Thomas Chief Scientific Officer |
108,000 | $0 | 213,719 (Direct) |
View |
| 2025-01-02 Option Award |
2025-01-03 8:10 pm |
N/A 2035-01-01 |
Janux Therapeutics Inc. | JANX | Dobek Maria Vice President, Accounting |
45,500 | $0 | 45,501 (Direct) |
View |
Ownership(A) |
2025-01-03 8:01 pm |
N/A N/A |
Janux Therapeutics Inc. | JANX | Winter Charles M. Chief Technical Officer |
0 | $0 | 46,111 (Direct) |
View |
Ownership |
2025-01-03 8:00 pm |
N/A 2033-05-31 |
Janux Therapeutics Inc. | JANX | McIver Zachariah Chief Medical Officer |
0 | $0 | 146,200 (Direct) |
View |
| 2025-01-02 Option Award |
2025-01-03 5:10 pm |
N/A 2035-01-01 |
Janux Therapeutics Inc. | JANX | Meyer Andrew Hollman Chief Business Officer |
81,000 | $0 | 145,139 (Direct) |
View |
| 2024-12-19 Exercise |
2024-12-20 6:25 pm |
N/A 2032-01-02 |
Janux Therapeutics Inc. | JANX | Meyer Andrew Hollman Chief Business Officer |
9,881 | $0 | 264,342 (Direct) |
View |
| 2024-12-19 Exercise |
2024-12-20 6:25 pm |
N/A N/A |
Janux Therapeutics Inc. | JANX | Meyer Andrew Hollman Chief Business Officer |
9,880 | $20.24 | 264,342 (Direct) |
View |
| 2024-12-19 Exercise |
2024-12-20 6:25 pm |
N/A N/A |
Janux Therapeutics Inc. | JANX | Meyer Andrew Hollman Chief Business Officer |
1 | $14.02 | 264,342 (Direct) |
View |
| 2024-11-05 Other |
2024-11-07 7:09 pm |
N/A N/A |
Janux Therapeutics Inc. | JANX | Gujrathi Sheila Director |
4,611 | $0 | 119,750 (Direct) |
View |
| 2024-11-05 Other |
2024-11-07 7:08 pm |
N/A N/A |
Janux Therapeutics Inc. | JANX | CAPPS VICKIE L Director |
2,305 | $0 | 72,653 (Direct) |
View |
| 2024-09-13 Exercise |
2024-10-24 4:15 pm |
N/A N/A |
Janux Therapeutics Inc. | JANX | Lichter Jay 10% Owner |
391 | $39.8 | 6,618,252 (Direct) |
View |
| 2024-09-13 Exercise |
2024-10-24 4:15 pm |
N/A 2027-07-19 |
Janux Therapeutics Inc. | JANX | Lichter Jay 10% Owner |
3,815 | $0 | 6,618,252 (Direct) |
View |
| 2024-09-13 Exercise |
2024-10-24 4:15 pm |
N/A N/A |
Janux Therapeutics Inc. | JANX | Lichter Jay 10% Owner |
1,868 | $17 | 6,618,252 (Direct) |
View |
| 2024-09-13 Exercise |
2024-10-24 4:15 pm |
N/A N/A |
Janux Therapeutics Inc. | JANX | Lichter Jay 10% Owner |
778 | $10.73 | 6,618,252 (Direct) |
View |
| 2024-09-13 Exercise |
2024-10-24 4:15 pm |
N/A N/A |
Janux Therapeutics Inc. | JANX | Lichter Jay 10% Owner |
778 | $13.22 | 6,618,252 (Direct) |
View |
| 2024-10-16 Exercise |
2024-10-18 6:51 pm |
N/A N/A |
Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner |
1,644 | $39.8 | 4,281,533 (Direct) |
View |
| 2024-10-16 Exercise |
2024-10-18 6:51 pm |
N/A 2027-07-19 |
Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner |
12,284 | $0 | 4,281,533 (Direct) |
View |
| 2024-10-16 Exercise |
2024-10-18 6:51 pm |
N/A N/A |
Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner |
5,804 | $17 | 4,281,533 (Direct) |
View |
| 2024-10-16 Exercise |
2024-10-18 6:51 pm |
N/A N/A |
Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner |
2,418 | $10.73 | 4,281,533 (Direct) |
View |
| 2024-10-16 Exercise |
2024-10-18 6:51 pm |
N/A N/A |
Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner |
2,418 | $13.22 | 4,281,533 (Direct) |
View |
| 2024-09-27 Exercise |
2024-09-30 8:49 pm |
N/A N/A |
Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner |
357 | $39.8 | 3,005,777 (Direct) |
View |
| 2024-09-27 Exercise |
2024-09-30 8:49 pm |
N/A 2027-07-19 |
Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner |
2,671 | $0 | 3,005,777 (Direct) |
View |
| 2024-09-27 Exercise |
2024-09-30 8:49 pm |
N/A N/A |
Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner |
1,262 | $17 | 3,005,777 (Direct) |
View |
| 2024-09-27 Exercise |
2024-09-30 8:49 pm |
N/A N/A |
Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner |
526 | $10.73 | 3,005,777 (Direct) |
View |
| 2024-09-27 Exercise |
2024-09-30 8:49 pm |
N/A N/A |
Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner |
526 | $13.22 | 3,005,777 (Direct) |
View |
| 2024-09-27 Exercise |
2024-09-27 7:32 pm |
N/A 2031-03-09 |
Janux Therapeutics Inc. | JANX | Meyer Andrew Hollman Chief Business Officer |
50,000 | $0 | 168,259 (Direct) |
View |
| 2024-09-27 Exercise |
2024-09-27 7:32 pm |
N/A N/A |
Janux Therapeutics Inc. | JANX | Meyer Andrew Hollman Chief Business Officer |
50,000 | $4.21 | 168,259 (Direct) |
View |
| 2024-09-09 Exercise |
2024-09-10 5:02 pm |
N/A N/A |
Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner |
277 | $39.8 | 3,297,625 (Direct) |
View |
| 2024-09-09 Exercise |
2024-09-10 5:02 pm |
N/A 2027-07-19 |
Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner |
2,099 | $0 | 3,297,625 (Direct) |
View |
| 2024-09-09 Exercise |
2024-09-10 5:02 pm |
N/A N/A |
Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner |
994 | $17 | 3,297,625 (Direct) |
View |
| 2024-09-09 Exercise |
2024-09-10 5:02 pm |
N/A N/A |
Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner |
414 | $10.73 | 3,297,625 (Direct) |
View |
| 2024-09-09 Exercise |
2024-09-10 5:02 pm |
N/A N/A |
Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner |
414 | $13.22 | 3,297,625 (Direct) |
View |
Ownership |
2024-08-09 7:06 pm |
N/A 2031-03-09 |
Janux Therapeutics Inc. | JANX | Dobek Maria Vice President, Accounting |
0 | $0 | 73,698 (Direct) |
View |
| 2024-07-19 Option Award(A) |
2024-07-24 8:00 pm |
N/A 2034-07-18 |
Janux Therapeutics Inc. | JANX | DOBMEIER ERIC Director |
5,342 | $0 | 10,342 (Direct) |
View |
| 2024-07-19 Option Award(A) |
2024-07-24 8:00 pm |
N/A 2034-07-18 |
Janux Therapeutics Inc. | JANX | Hernday Natasha Director |
5,342 | $0 | 10,342 (Direct) |
View |
| 2024-07-19 Option Award |
2024-07-22 8:04 pm |
N/A 2034-07-18 |
Janux Therapeutics Inc. | JANX | DOBMEIER ERIC Director |
32,550 | $0 | 32,550 (Direct) |
View |
| 2024-07-19 Option Award |
2024-07-22 8:03 pm |
N/A 2034-07-18 |
Janux Therapeutics Inc. | JANX | Hernday Natasha Director |
32,550 | $0 | 32,550 (Direct) |
View |
| 2024-06-26 Option Award |
2024-06-28 4:35 pm |
N/A 2034-06-25 |
Janux Therapeutics Inc. | JANX | RA CAPITAL MANAGEMENT L.P. RA Capital Healthcare Fund LP RA Capital Nexus Fund II L.P. Kolchinsky Peter Shah Rajeev M. Director 10% Owner |
10,850 | $0 | 9,176,502 (Indirect) |
View |
| 2024-06-26 Option Award |
2024-06-28 4:30 pm |
N/A 2034-06-25 |
Janux Therapeutics Inc. | JANX | Lichter Jay Director 10% Owner |
10,850 | $0 | 7,260,340 (Direct) |
View |
| 2024-06-26 Option Award |
2024-06-28 4:30 pm |
N/A 2034-06-25 |
Janux Therapeutics Inc. | JANX | McNulty Alana B. Director |
10,850 | $0 | 10,850 (Direct) |
View |
| 2024-06-26 Option Award |
2024-06-28 4:30 pm |
N/A 2034-06-25 |
Janux Therapeutics Inc. | JANX | Kung Winston Director |
10,850 | $0 | 10,850 (Direct) |
View |